In this study, we showed that a codon optimized version of the spike (S) protein of SARS-
CoV-2 can migrate to the cell membrane. However, efficient production of Moloney murine …

The rapid evolution of new SARS-CoV-2 variants poses a continuing threat to human health.
Vaccination has become the primary therapeutic intervention. The goal of the current work …

Coronavirus Disease 2019 (COVID-19), caused by infection with Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), has highlighted the need for the rapid generation …

Virus-like particles (VLPs) have been proposed as an attractive tool in SARS-CoV-2 vaccine
development, both as (1) a vaccine candidate with high immunogenicity and low …

Virus-like particles (VLPs) constitute a promising approach to recombinant vaccine
development. They are robust, safe, versatile and highly immunogenic supra-molecular …

The severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) Spike glycoprotein is
solely responsible for binding to the host cell receptor and facilitating fusion between the …

We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several …

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
threatened human health and the global economy. Development of additional vaccines and …

Background As the COVID-19 pandemic continues to evolve, novel vaccines need to be
developed that are readily manufacturable and provide clinical efficacy against emerging …

The robustness, safety, versatility, and high immunogenicity of virus-like particles (VLPs)
make them a promising approach for the generation of vaccines against a broad range of …